A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors

A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Malignant Tumors

This study is a single-dose, open-label, 2-cycle crossover design, comparing the pharmacokinetic parameters and safety of Inhaled Fentanyl Aerosol and intravenous fentanyl injection.

Study Overview

• Status: Recruiting
• Conditions: Cancer
• Intervention / Treatment: Drug: Inhaled Fentanyl Aerosol; Drug: Fentanyl Citrate Injection

Detailed Description

Consenting patients who met inclusion and exclusion criteria were allowed to enter the study. The subjects will be randomly assigned (1:1) to receive an intravenous bolus (5 seconds) of 25μg fentanyl injection in the first cycle, and after a 2-week washout period, to receive a single dose of 25μg inhaled fentanyl aerosol through the Staccato delivery system in the second cycle; or to receive the same treatment in the opposite order.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Haiyan Hu, doctor; Phone Number: +86 18930174575; Email: xurill@163.com

Study Locations

• China
  • Henan
    • Zhengzhou, Henan, China, 450008
      • Recruiting
      • Henan Tumor Hospital
      • Contact: Luo Suxia, doctor; Phone Number: +86 0371-65587320; Email: luosxrm@163.com
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China, 200233
      • Not yet recruiting
      • Shanghai Sixth People's Hospital
      • Contact: Haiyan Hu, doctor; Phone Number: +86 18930174575; Email: xurill04@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Volunteer to participate, understand and sign the informed consent form before conducting the evaluation project;
2. Male or female subjects, aged between 18 and 55, including 18 and 55 years old;
3. Patients with malignant tumors diagnosed by histology or cytology;
4. Body Mass Index (BMI) is >21 kg/m2, but <30 kg/m2;

5. Have sufficient hematopoietic function and organ function within the last 14 days at random.

   1. The absolute neutrophil count is ≥1.5×109/L (has not received colony stimulating factor treatment within 14 days before the examination);
   2. Platelet count ≥80×109/L (without transfusion of platelets or other platelet-increasing drugs within 14 days before the examination);
   3. Hemoglobin ≥90g/L (without transfusion or treatment with other hemoglobin-increasing drugs within 7 days before the examination);
   4. Creatinine clearance rate (Ccr)≥30 ml/min, Cr≤2 times the upper limit of normal value;
   5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) should be ≤2.5×ULN, and for subjects with liver metastasis, it should be ≤5×ULN; total bilirubin should be ≤2 times the upper limit of normal value;
   6. Coagulation function INR≤1.5 ULN;
   7. In a non-oxygen-absorbing state, the oxygen saturation (from a pulse oximeter) is SaO2>95%; pulmonary function shows FEV1/FVC>70% and FEV1 as a percentage of the predicted value is>80%;
6. All patients must agree to take effective contraceptive measures during the study and within one month after stopping treatment. Female patients of childbearing age must have a negative blood pregnancy test before administration;
7. The ECOG performance status score is 0~1 points;

Exclusion Criteria:

1. known or suspected allergy to opioids;
2. used opioids within 14 days before the first administration, including but not limited to: codeine, dihydrocodeine, hydromorphone, oxycodone, methadone, morphine, fentanyl and pethidine (pethidine);
3. plan to receive radiotherapy and / or systemic chemotherapy within 14 days before the first administration or during the study period (except for patients who receive immune checkpoint inhibitors or targeted drug maintenance therapy that is not a CYP3A4 inhibitor / inducer and whose condition is stable);
4. within 14 days before the first administration, the patient had received any monoamine oxidase (MAO) inhibitors (such as phenelzine, isocarbazine, chlorogiline, toloxadone, moclobemide, selegiline, rasagiline, etc.); Or have used CYP3A4 inhibitors (such as indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, nefazodone, ketoconazole, telithromycin, arepitan, erythromycin, fluconazole, grapefruit, verapamil, diltiazem, cimetidine, etc.) or CYP3A4 inducers (such as phenobarbital, carbamazepine, efavirenz, glucocorticoids, modafinil, nevirapine, oxcarbazepine, phenytoin, pioglitazone, rifabutin, rifampicin);
5. have participated in other clinical studies or received surgical treatment within 30 days before the screening period, or have surgery plans during the study period;
6. subjects who smoked more than 10 cigarettes / day within 3 months before the screening period;
7. subjects with a history of drug or alcohol dependence or abuse within 2 years before the screening period;
8. subjects often eat food rich in xanthine (such as drinking more than 5 cups of coffee or food containing the same amount of xanthine every day);
9. subjects with hypotension (systolic blood pressure <90 mmHg, or diastolic blood pressure <60 mmHg) or uncontrollable hypertension (refers to systolic blood pressure ≥ 160 mmHg, and / or diastolic blood pressure ≥ 100 mmHg after standard treatment);
10. After antiviral treatment, HBV DNA>500 IU/mL or>2500 copies/mL; HCV-RNA positive; Positive for human immunodeficiency virus antibodies; Or positive for syphilis antibodies;
11. subjects with positive alcohol test or urine test at any visit of the study;
12. subjects with an expected survival time of <1 year;
13. subjects with clinically significant ECG abnormalities during screening;
14. subjects with a history of lung diseases (asthma, bronchitis, bronchospasm, emphysema, interstitial lung disease, pulmonary fibrosis, etc., excluding lung malignancies);
15. subjects with history of unstable angina pectoris, syncope, coronary artery disease, myocardial infarction, congestive heart failure (CHF), stroke, transient ischemic attack (TIA) or major neurological diseases;
16. presence of meningeal metastasis or CNS metastasis requiring clinical intervention or malignancy related epilepsy;
17. women of childbearing age or lactating women with positive blood and urine pregnancy tests;
18. the investigator believes that any other situation that may affect the subject's provision of informed consent or compliance with the trial protocol, or the subject's participation in the trial may affect the trial results or their own safety.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental:Inhaled fentanyl aerosol; Subjects will be randomly assigned (1:1) to either drug sequence	Drug: Inhaled Fentanyl Aerosol; The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg Fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg Fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.
Active Comparator: Active Comparator:Fentanyl Citrate Injection; Subjects will be randomly assigned (1:1) to either drug sequence	Drug: Fentanyl Citrate Injection; The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Peak Concentration	Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration
Tmax	Time to Maximum Concentration	Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration
Ke	Terminal Elimination Rate	Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration
T1/2	Terminal elimination half-life	Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration
CL/F	Apparent Clearance (CL/F)	Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration
AUC_last	Area Under the Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration	Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration
AUC_inf	Area Under the Concentration-Time Curve from Time Zero to Infinity	Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pupil diameter	Measure the pupil diameter using a pupillometer.	Pupil measurements were taken before administration, and at 1, 2, 3, 5 , 10 , 30minutes , and 1, 2, 4, 8, 12 and 18hours after drug administration.

Collaborators and Investigators

• Sponsor: Lee's Pharmaceutical Limited
• Investigators: Principal Investigator: Haiyan Hu, doctor, Shanghai 6th People's Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 23, 2025
• Primary Completion (Estimated): July 20, 2026
• Study Completion (Estimated): August 20, 2026

Study Registration Dates

• First Submitted: April 16, 2025
• First Submitted That Met QC Criteria: April 23, 2025
• First Posted (Actual): May 1, 2025

Study Record Updates

• Last Update Posted (Estimated): September 25, 2025
• Last Update Submitted That Met QC Criteria: September 24, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Piperidines; Fentanyl
• Other Study ID Numbers: ZK07

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No